Altimmune shares cratered nearly 60% on Thursday after its experimental obesity drug did not significantly improve liver ...

Altimmune said on Thursday its experimental obesity drug met the main goal of a mid-stage trial studying it as a potential treatment for a fatty liver disease. The drug, pemvidutide, showed a ...

Altimmune stock took a huge hit after its liver disease drug, pemvidutide, failed to show strong results in reducing fibrosis ...

Altimmune's Phase 2b trial of pemvidutide showed significant MASH resolution, liver fat reduction, and favorable safety ...

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...

Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 ...

Altimmune Inc (NASDAQ: ALT) shares plunged after topline results from its 12-week Phase 1b study of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD). The trial assessed three ...

Shares of Altimmune Inc. tumbled 44.4% in premarket trading on Wednesday after the company shared new data from an early-stage clinical trial for its experimental treatment for non-alcoholic fatty ...

Altimmune shares rose 13% in premarket trading following an announcement it would present topline 24-week data from its Phase 2b trial evaluating pemvidutide as a treatment for those with metabolic ...

Findings support the potential benefit of pemvidutide on co-morbidities of metabolic dysfunction-associated steatohepatitis (MASH), including atherosclerosis, heart disease and metabolic syndrome ...

Altimmune Inc (NASDAQ: ALT) announced topline results from its 24-week (12-week extension) trial of pemvidutide in subjects with Non-Alcoholic Fatty Liver Disease (NAFLD). Sixty-six of the 83 ...

The latest international Altimmune Inc news and views from Reuters - one of the world's largest news agencies. ... Madrigal's drug wins first US approval for fatty liver disease NASH as rivals circle.